New concepts regarding the assessment of ischemic myocardial injuries have been addressed in this Minireview using magnetic resonance imaging (MRI). MRI, with its different techniques, brings not only anatomic, but also physiologic, information on ischemic heart disease. It has the ability to measure identical parameters in preclinical and clinical studies. MRI techniques provide the ideal package for repeated and noninvasive assessment of myocardial anatomy, viability, perfusion, and function. MR contrast agents can be applied in a variety of ways to improve MRI sensitivity for detecting and assessing ischemically injured myocardium. With MR contrast agents protocol, it becomes possible to identify ischemic, acutely infarcted, and peri-infarcted myocardium in occlusive and reperfused infarctions. Necrosis specific and nonspecific extracellular contrast-enhanced MRI has been used to assess myocardial viability. Contrast-enhanced perfusion MRI can explore the disturbances in large (angiography) and small coronary arteries (myocardial perfusion) as the underlying cause of myocardial dysfunction. Perfusion MRI has been used to measure myocardial perfusion (ml/min/g) and to demonstrate the difference in transmural myocardial blood flow. Information on no-reflow phenomenon is derived from dynamic changes in regional signal intensity after bolus injection of MR contrast agents. Another development is the near future availability of blood pool MR contrast agents. These agents are able to assess microvascular permeability and integrity and are advantageous in MR angiography (MRA) due to their persistence in the blood. Non-contrast-enhanced MRI such as cine MRI at rest/stress, sodium MRI, and MR spectroscopy also have the potential to noninvasively assess myocardial viability in patients. Futuristic applications for MRI in the heart will focus on identifying coronary artery disease at an early stage and the beneficial effects of new therapeutic agents such as intra-arterial gene therapy. MR techniques will have great future in the drug discovery process and in testing the effects of drugs on myocardial biochemistry, physiology, and morphology. Molecular imaging is going to bloom in this decade.
LernerDJ, KannalWB. Patterns of coronary heart disease mobility and mortality in the sexes: A 26-year follow up of the Framingham population. Am Heart J111:383–390, 1986.
2.
American Heart Association. Heart and Stroke Facts. Dallas, TX: American Heart Association Press, pp1–2, 1992.
3.
ItoH, TomookaT, SakaiN, YuH, HigashinoY, FujiiK, MasuyanaT, KitabatakeA, MinaminoT.Lack of myocardial perfusion immediately after successful thrombolysis: A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation85:1699–1705, 1992.
4.
TopolEJ, HerskowitzA, HutchinsGM. Massive hemorrhagic myocardial infarction after coronary thrombolysis. Am J Med81:339–343, 1986.
5.
JeremyRW, LinksJM, BeckerLC. Progressive failure of coronary flow during reperfusion of myocardial infarction: Documentation of the no-reflow phenomenon with positron emission tomography. J Am Coll Cardiol16:695–704, 1990.
6.
AsanumaT, TanabeK, OchiaiK, YoshitomiH, NakamuraK, MurakamiY, SanoK, ShimadaT, MurakamiR, MoriokaS, BeppuS.Relationship between progressive microvascular damage and intramyocardial hemorrhage in patients with reperfused anterior myocardial infarction. Circulation96:448–453, 1997.
RungeVM. Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging12:205–213, 2000.
9.
LaufferRB. Paramagnetic metal complexes as water proton relaxation agents for NMR imaing: Theory and design. Chem Rev87:901–923, 1987.
10.
KellerKE, HenrichsPM, SpillerM, KoenigHS. Relaxation of solvent protons by solute Gd+3-chelates, revisited. Magn Reson Med37:730–735, 1997.
11.
FullertonGD. Physiologic basis of magnetic relaxation. In: Stark DD, WG Bradley, Eds. Magnetic Resonance Imaging. St. Louis, MO: Mosby Year Book, Inc., pp88 Magnetic Resonance Imaging 108, 1992.
12.
KowalewskiJ, NordenskioldL, BenetisN, WestlundPO. Theory of nuclear relaxation in paramagnetic systems in solution. Prog NMR Spectroscopy17:141–185, 1985.
13.
TaylorAM, PantingJR, KeeganJ, GatehousePD, AminD, JhootiP, YangGZ, McGillS, BurmanED, FrancisJM, FirminDN, PennellDJ. Safety and preliminary findings with the intravascular contrast agent NC100150 injection for MR coronary angiography. J Magn Reson Imaging9:220–227, 1999.
14.
BraschRC. New directions in the development of MR imaging contrast media. Radiology183:1–11, 1992.
15.
WangSC, WikstromMG, WhiteDL, KlavenessJ, HoltzE, RongvedP, MoseleyME, BraschRC. Evaluation of Gd-DTPA-labeled dextran as an intravascular MR contrast agent: Imaging characteristics in normal rat tissues. Radiology175:483–488, 1990.
16.
AdamG, NeuerburgJ, SpuntrupE, MuhlerA, SchererK, GuntherRW. Gd-DTPA-cascade-polymer: Potential blood pool contrast agent for MR imaging. J Magn Reson Imaging4:462–466, 1994.
SaeedM, WendlandMF, MasuiT, HigginsCB. Reperfused myocardial infarctions on T1- and susceptibility-enhanced MRI: Evidence for loss of compartmentalization of contrast media. Magn Reson Med31:31–39, 1994.
19.
GeschwindJF, WendlandMF, SaeedM, LauermaK, DeruginN, HigginsCB. Identification of myocardial cell death in reperfused myocardial injury using dual mechanisms of contrast-enhanced magnetic resonance imaging. Acad Radiol1:319–325, 1994.
20.
BremerichJ, SaeedM, ArhedenH, HigginsCB, WendlandMF. Normal and infarcted myocardium: Differentiation with cellular uptake of manganese at MR imaging in a rat model. Radiology216:524–530, 2000.
21.
BrurokH, Ardenkjaer-LarsonJH, HanssonG, SkarraS, BergK, KarlssonJO, LaursenL, JyngeP.Manganese dipyridoxyl diphosphate: MRI contrast agent with antioxidative and cardioprotective properties?Biochem Biophys Res Commun254:768–772, 1999.
22.
WendlandMF, SaeedM, LundG, HigginsCB. Contrast-enhanced MRI for qualification of myocardial viability. J Magn Reson Imaging10:694–702, 1999.
23.
DiesbourgLD, PratoFS, WisenbergG, DrostDJ, MarshallTP, CarrollSE, O'NeillB.Quantification of myocardial blood flow and extracellular volumes using a bolus injection of Gd-DTPA: Kinetic modeling in canine ischemic disease. Magn Reson Med23:239–253, 1992.
24.
TongCY, PratoFS, WisenbergG, LeTY, CarrollE, SandlerD, WillsJ, DrostD.Measurement of the extraction efficiency and distribution volume for Gd-DTPA in normal and diseased canine myocardium. Magn Reson Med30:337–346, 1993.
25.
WendlandMF, SaeedM, LauermaKDeruginN, MintorovichJ, CavagnaFM, HigginsCB. Alterations in T1 of normal and reperfused infarcted myocardium after Gd-BOPTA versus Gd-DTPA on inversion recovery EPI. Magn Reson Med37:448–456, 1997.
26.
HarrisPA, LorenzCH, HolburnGE, OverholsterKA. Regional measurement of the Gd-DTPA tissue partition coefficient in canine myocardium. Magn Reson Med38:541–545, 1997.
27.
DendaleP, FrankenPR, BlockP, PratikakisY, de RoosA.Contrast-enhanced and functional magnetic resonance imaging for the detection of viable myocardium after infarction. Am Heart J135:875–880, 1998.
WuKC, ZerhouniEA, JuddRM, Lugo-OlivieriCH, BarouchLA, SchulmanSP, BlumentalRS, LimaJA. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation97:765–772, 1998.
30.
LimaJA, JuddRM, BazilleA, SchulmanSP, AtalarE, ZerhouniEA. Regional heterogeneity of human myocardial infarcts demonstrated by contrast-enhanced MRI: Potential mechanisms. Circulation92:1117–1125, 1995.
31.
PereiraRS, PratoFS, WisenbergG, SykesJ.The determination of myocardial viability using Gd-DTPA in a canine model of acute myocardial ischemia and reperfusion. Magn Reson Med36:684–693, 1996.
32.
ArhedenH, SaeedM, HigginsCB, GaoDW, BremerichJ, WattynbachR, DaeMW, WendlandMF. Measurement of the distribution volume of gadopentatate dimeglumine at echo-planar MR imaging to quantify myocardial infarction: Comparison with 99mTc-DTPA autoradiography in rats. Radiology211:698–708, 1999.
33.
SaeedM, HigginsCB, GeschwindJF, WendlandMF. T1-relaxation kinetics of extracellular, intracellular, and intravascular MR contrast agents in normal and acutely reperfused infarcted myocardium using echoplanar MR imaging. Eur Radiol10:310–318, 2000.
34.
ArhedenH, SaeedM, HigginsC, UrsellPC, BremerichJ, WattenbachR, DaeMW, WendlandMF. Reperfused rat myocardium subjected to various duration of ischemia: Estimation of the distribution volume of contrast material using echoplanar MR imaging. Radiology215:520–528, 2000.
35.
PolimeniPI. Extracellular space and ionic distribution in rat ventricle. Am J Physiol227:676–683, 1974.
36.
MacchiaDD, PageE, PolimeniPI. Interstitial anion distribution in striated muscle determined with [35S]sulfate and [3H]sucrose. Am J Physiol237:C125–C130, 1979.
37.
ManningWJ, AtkinsonDJ, GrossmanW, PaulinS, EdelmannRR. First pass nuclear magnetic resonance imaging studies using Gadolinium-DTPA in patients with coronary artery disease. J Am Coll Cardiol18:959–965, 1991.
38.
WyttenbachR, SaeedM, WendlandMF, GeschwindJF, BremerichJ, ArhedenH, HigginsCB. Detection of acute myocardial ischemia using first-pass dynamic of MN-DPDP on inversion recovery echo planar imaging. J Magn Reson Imaging9:209–214, 1999.
39.
SchwitterJ, SaeedM, WendlandMF, SakumaH, BremerichJ, CanetE, HigginsCB. Assessment of myocardial function and perfusion in a canine model of non-occlusive coronary artery stenosis using fast magnetic resonance imaging. J Magn Reson Imaging9:101–110, 1999.
40.
SaeedM, WendlandMF, SakumaH, GeschwindJF, DerugunN, CavagnaFM, HigginsCB. Coronary artery stenosis: Detection with contrast-enhanced MR imaging in dogs. Radiology196:79–84, 1995.
41.
van RossumAC, VisserFC, Van EenigeMJ, SprengerM, ValkJ, VerheugtFW, RoosJP. Value of gadolinium-diethylene-triamine pentaacetic acid dynamics in magnetic resonance imaging of acute myocardial infarction with occluded and reperfused coronary arteries after thrombolysis. Am J Cardiol65:845–851, 1990.
42.
HigginsCB, SaeedM, WendlandMF, BourneM, SteffansJ, SakumaH.Evaluation of myocardial function and perfusion in ischemic heart disease. MAGMA2:177–184, 1994.
43.
KleinMA, CollierBD, HellmanRS, BamrahVS. Detection of chronic coronary artery disease: Value of pharmacological stressed, dynamically enhanced turbo-fast low-angle shot MR images. Am J Roentgenol161:257–263, 1993.
44.
BremerichJ, BuserP, BongartzG, Muller-BrandJ, GraedelC, PfistereM, SteinbrichW.Noninvasive stress testing of myocardial ischemia: Comparison of MRI perfusion and wall motion analysis to 99mTc-MIBI SPECT, relation to coronary angiography. Eur Radiol7:990–995, 1997.
45.
LauermaK, VirtanenKS, SipilaLm, HekaliP, AronenHJ. Multislice single-vessel proximal left anterior descending coronary artery disease before and after revascularization. Circulation96:2859–2867, 1997.
46.
SzolarDH, SaeedM, WendlandMF, SakumaH, RobertsTP, StiskalMA, DeruginN, HigginsCB. MR imaging characterization of postischemic myocardial dysfunction (“stunned myocardium”): Relationship between functional and perfusion abnormalities. J Magn Reson Imaging6:615–624, 1996.
47.
SaeedM, WendlandMF, SzolarD, SakumaH, GeschwindJF, GlobitsS, DeruginN, HigginsCB. Quantification of the extent of area at risk with fast contrast-enhanced magnetic resonance imaging in experimental coronary artery stenosis. Am Heart J132:921–932, 1996.
48.
RochitteCE, LimaJA, BluemkeDA, ReederSB, McVeighER, FurutaT, BeckerLC, MelinJA. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation98:1006–1014, 1998.
49.
SaeedM, WendlandMF, YuKK, LauermaK, LiHT, DeruginN, CavagnaFM, HigginsCB. Identification of myocardial reperfusion with echo planar magnetic resonance imaging: Discrimination between occlusive and reperfused infarctions. Circulation90:1492–1501, 1994.
50.
GerberBL, BluemkeDA, ChinnBB, HeldmanA, LimaJA, KraitchmanDL. Comparison between Gadomer-17 and gadolinmium DTPA for the assessment of myocardial perfusion using first pass MRI in a swine model of single vessel coronary artery stenosis. Radiology217:130, 2000.
51.
KimRJ, FienoDS, ParrishTB, HarrisK, ChenEL, SimonettiO, BundyJ, FinnJP, KlockeFJ, JuddRM. Relationship of MRI delayed contrast enhancement to reversible injury, infarct age and contractile function. Circulation100:1992–2002, 1999.
52.
RamaniK, JuddRM, HollyRA, ParrishTB, RigolinVH, ParkerMA, CallahanC, FritzgeraldSW, BonowRO, KlockeFJ. Contrast magnetic resonance imaging in the assessment of myocardial viability in patients with stable coronary artery disease and left ventricular dysfunction. Circulation98:2687–2694, 1998.
53.
JuddRM, Lugo-OlivieriCH, AraiM, KondoT, CroisilleP, LimaJA, MohanV, BeckerLC, ZerhouniEA. Physiological basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts. Circulation92:1902–1910, 1995.
54.
GerberBL, RochitteCS, MelinJA, McVeighER, BluemkeDA, WuKC, BeckerLC, LimaJA. Microvascular obstruction and left ventricular remodeling early after acute myocardial infarction. Circulation101:2734–2741, 2000.
55.
AmbrosioG, WeismanHF, MannisiJA, BeckerLC. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation80:1846–1861, 1989.
56.
KlonerRA, GanoteCE, JenningsRB. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest54:1496–1508, 1974.
57.
WuKC, KimRJ, BluemkeDA, RochitteCE, ZerhouniEA, BeckerLC, LimaJA. Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. J Am Coll Cardiol32:1756–1764, 1998.
58.
SandstedeJJW, LipkeC, BerM, HarreK, PabstT, KennW, NeubauerS, HahnD.Analysis of first and delayed contrast-enhancement patterns of dysfunctional myocardium on MR imaging: Use in the prediction of myocardial viability. Am J Roentg174:1737–1740, 2000.
59.
SaeedM, BremerichJ, WendlandMF, WyttenbachR, WeinmannHJ, HigginsCB. Reperfused myocardial infarction as seen with use of necrosis-specific versus standard extracellular MR contrast media in rats. Radiology213:247–257, 1999.
60.
SaeedM, LundG, WendlandMF, WeinmannHJ, HigginsCB. MR evaluation of the peri-infarction zone in postischemic myocardium using functional and contrast-enhanced MR imaging. Radiology217:241, 2000.
61.
StillmanAE, WilkeN, Jerosch-HeroldM.Myocardial viability. Radiol Clin North Am37:361–378, 1999.
62.
KramerCM. Integrated approach to ischemic heart disease: The one-stop shop. Cardiol Clin16:267–276, 1998.
63.
WeisslederR, LeeA, KhawB, ShenT, BradyT.Detection of myocardial infarction with MION-antimyosin. Radiology182:381–385, 1992.
64.
MarchalG, NiY, HerijgersP, FlamengW, PetreC, BosmansH, YuJ, EbertW, HilgerCS, PfefferD, SemmlerW, BaertAL. Paramagnetic metalloporphyrins: Infarct avid contrast agents for diagnosis of acute myocardial infarction by MRI. Eur Radiol6:2–8, 1996.
65.
NiY, MarchalG, HerijgersP, FlamengW, MiaoY, BogaertJ.DymarkowskiS, SemmlerW, MarkelW, van de WerfFJ. Paramagnetic metalloporphyrins: From enhancers of malignant tumors to markers of myocardial infarcts. Acad Radiol3(Suppl 2):S395–S397, 1996.
66.
PislaruSV, NiY, PislaruC, BosmansH, MiaoY, BoggertJ, DymarkowskiS, SemmlerW, MarchalG, van FransJ.Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent. Circulation99:690–696, 1999.
67.
WeisslederR.Molecular imaging: Exploring the next frontier. Radiology212:609–614, 1999.
SaeedM, LundG, WendlandMF, WatzigerN, WeinmannHJ, HigginsCB. The cardioprotective effects of nicorandil in ischemically injured myocardium depicted by necrosis-specific and standard extracellular MR contrast media. Radiology217:465, 2000.
70.
GallezB, BacicG, SwartzH.Evidence for the dissociation of the hepatobiliry MRI contrast agent Mn-DPDP. Magn Reson Med35:14–19, 1996.
71.
BrurokH, SchjottJ, BergK, KarlssonJO, JyngeP.Effects of Mn DPDP, DPDP, and MnCl2 on cardiac energy metabolism and manganese accumulation: An experimental study in the isolated perfused rat heart. Invest Radiol32:205–211, 1997.
72.
Van der EistL, ColetJM, MullerRN. Spectroscopic and metabolic effects of MnCl2 and MnDPDP on the isolated and perfused rat heart. Invest Radiol32:581–588, 1997.
73.
PomeroyOH, WendlandM, WagnerS, DeruginN, HoltWW, Rock-lageSM, QuayS, HigginsCB. Magnetic resonance imaging of acute myocardial ischemia using a manganese chelate, Mn-DPDP. Invest Radiol24:531–536, 1989.
74.
SaeedM, WagnerS, WendlandMF, DeruginN, FinkbeinerWE, HigginsCB. Occlusive and reperfused myocardial infarcts: Differentiation with Mn-DPDP-enhanced MR imaging. Radiology172:59–64, 1989.
75.
PennelDJ, UnderwoodRS, EllPJ, SwanntonRH, WalkerJM, Long-moreDB. Dipyridamole magnetic resonance imaging: A comparison with thallium-201 emission tomography. Br Heart J64:362–369, 1990.
76.
BaerFM, VothE, SchneiderCA, TheissenP, SchichaH, SechtemD.Comparison of low-dose dobutamine-gradient echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease: A functional and morphological approach to the detection of residual myocardial viability. Circulation91:1006–1015, 1995.
BaerFM, TheissenP, SchneiderCA, VothE, SechtemU, SchichaH, ErdmannE.Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunction myocardium after successful revascularization. J Am Coll Cardiol31:1040–1048, 1998.
79.
ZerhouniEA, ParishDM, RogersWJ, YangA, ShapiroEP. Human heart: Tagging with MR imaging a method for noninvasive assessment of myocardial motion. Radiology169:59–63, 1988.
80.
AxelL, DoughertyL.Heart wall motion: Improved method of spatial modulation of magnetization for MR imaging. Radiology172:349–356, 1989.
81.
YoungAA, KramerCM, FerrariL, AxelN, ReicheckN.Three-dimensional left ventricular deformation in hypertrophic cardiomyopathy. Circulation90:854–867, 1994.
82.
KramerCM, LimaJA, ReicheckN, FerrariVA, LianerasMR, PalmonLC, YehIT, TallantB, AxelL.Regional differences in function within noninfarcted myocardium during left ventricular remodeling. Circulation88:1279–1288, 1993.
CannonPJ, MaudsleyAA, HilalSK, SimonHE, CassidyF.Sodium nuclear magnetic resonance imaging of myocardial tissue of dogs after coronary artery occlusion and reperfusion. J AM Coll Cardiol7:573–579, 1986.
85.
KimRJ, LimaJA, ChenEI, ReederSB, KlockeFJ, ZerhouniEA, JuddRM. Fast 23Na magnetic resonance imaging of acute reperfused myocardial infarction: Potential to assess myocardial viability. Circulation95:1877–1885, 1997.
86.
SaeedM, WendlandMF, WagnerS, DeruginN, HigginsCB. Preservation of high-energy phosphate reserves in a cat model of postischemic myocardial dysfunction. Invest Radiol27:145–152, 1992.
87.
HigginsCB, SaeedM, WendlandMF, ChewWM. Magnetic resonance spectroscopy of the heart: Overview of studies in animals and man. Invest Radiol24:962–968, 1990.
88.
HoltWW, WendlandMF, DeruginN, WolfeC, SaeedM, HigginsCB. Effects of nicardipine, a calcium channel antagonist, on myocardial salvage and high energy phosphate stores in reperfused myocardial injury. J Am Coll Cardiol16:1736–1744, 1990.
89.
WeissRG, BottomleyPA, HardyCJ, GerstenblithG.Regional myocardial metabolism of high-energy phosphates during isometric exercise in patients with coronary artery disease. New Engl J Med323:1593–1600, 1990.
90.
BottomleyPA, WeissRG. Non-invasive magnetic resonance detection of creatine depletion in non-viable infarcted myocardium. Lancet351:714–718, 1998.
91.
PohostGM. Is 31P-NMR spectroscopic imaging a viable approach to assess myocardial viability?Circulation92:9–10, 1995.
92.
KraitchmanDL, WilkeN, HexebergH, Jerosch-HeroldM, WangY, ParrishTB, ChangCN, ZhangY, BacheRJ, AxelL.Myocardial perfusion and function in dogs with moderate coronary stenosis. Magn Reson Med35:771–780, 1996.
93.
KraitchmanDL, YoungAA, BloomgardenDC, FayadZA, DoughertyL, FerrariVA, BostonRC, AxelL.Integrated MRI assessment of regional function and perfusion in canine myocardial infarction. Magn Reson Med40:311–328, 1998.
94.
EichenbergerAC, SchuikiE, KochliVD, AmannFW, McKinnonGC, von SchulthessGK. Ishemic heart disease: assessment with gadolinium-enhanced ultrafast MR imaging and dipyridamole stress. J Magn Reson Imaging4:425–431, 1995.
